IN-STENT RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION AMONG CHRONIC AND NORMAL RENAL PATIENTS
No Thumbnail Available
Date
2025-11-12
Authors
Masime, Abdel-Hadi
Journal Title
Journal ISSN
Volume Title
Publisher
An-Najah National University
Abstract
Background: Chronic Kidney Disease (Scholz et al.) patients’ interface with high-risk cardiovascular diseases, but the relation among CKD and in stent restenosis (ISR) post percutaneous coronary intervention (PCI) still insufficiently distinguished. This study explores the prevalence, risk factors and outcomes of ISR in End Stage Renal Disease (ESRD) patients compared to normal renal patients.
Methods: A retrospective cohort study conducted at An-Najah National University Hospital, in Palestine for last 2 years. A Convince sample consist of 300 patients with 150 ESRD and 150 normal kidney patients who undergo PCI analyzed. Demographics data, comorbidities, procedural details and clinical outcomes were included.
Results: ESRD patients were significantly older (62.2 vs. 44.0) years, had higher rates of stroke (26% vs. 0%) and dyslipidemia (16% vs. 0%), but lower smoking rates (29.3% vs. 64.7%) with *p*<0.001 compared with normal renal patients. Regards stent insertion, ISR-linked procedural group have higher use of femoral/brachial access (ESRD: 60.7% vs. Normal: 0.00%), while Lower utilization of radial access for ESRD patients compared to Normal (39.4% vs. 100%).
Factors: Regards stent type compared among ESRD and normal renal patients bare-metal stents (34% vs. 0%) with *p*<0.001, advanced drug-eluting stents (e.g., Synsiro: 0% vs. 30%) with*p*<0.001).
ESRD patients presented more frequently with stable angina (25.3% vs. 0%; *p*<0.001) and shortness of breath (45.3% vs. 29.3%; *p*=0.004) but had shorter hospital stays post-PCI (5.2 vs. 75.5 days; *p*<0.001).
Conclusion: ESRD patients exhibit distinct demographic, clinical, and procedural profiles influencing ISR risk. CKD is an independent predictor of adverse PCI outcomes as the CKD patients linked to older age and other comorbidities compered to normal renal patients, necessitating tailored interventions. Optimizing stent selection and access strategies may mitigate ISR in this high-risk cohort.